ストックスクリーナーアプリを入手
1.73
2.81%
-0.05
アフターアワーズ：
1.73
前日終値:
$1.78
開ける：
$1.78
24時間の取引高:
144.74K
Relative Volume:
0.34
時価総額：
$244.64M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.35%
1か月 パフォーマンス:
-3.89%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.72
$1.825
1週間の範囲:
$1.72
$2.00
52週間の値動き範囲:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
1.73 | 267.26M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.52 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag (VRXA) 最新ニュース
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -
Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan
Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - The Manila Times
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga
Veraxa Biotech AG Ord Shs (VRXA) Institutional Confidence - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa
Veraxa Biotech AG Ord Shs (VRXA) Cash Flow - TradingKey
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Income Statement - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio - The Manila Times
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
Veraxa Biotech Ag (VRXA) 財務データ
Veraxa Biotech Ag (VRXA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.07%
1.21%
大文字化:
|
ボリューム (24 時間):